HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

succinobucol (AGI 1067)

monosuccinic acid ester of probucol; a metabolically stable modification of probucol, an equipotent antioxidant to probucol but is pharmacologically distinct
Also Known As:
AGI 1067; AGI-1067; AGI1067
Networked: 28 relevant articles (5 outcomes, 11 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Tardif, Jean-Claude: 9 articles (05/2008 - 01/2002)
2. L'Allier, Philippe L: 6 articles (05/2008 - 01/2002)
3. Grégoire, Jean: 5 articles (03/2008 - 01/2002)
4. Scott, Robert: 3 articles (05/2009 - 09/2006)
5. Malinin, Alex: 3 articles (05/2009 - 09/2006)
6. Serebruany, Victor: 2 articles (05/2009 - 09/2006)
7. Tomillero, A: 2 articles (09/2008 - 07/2008)
8. Moral, M A: 2 articles (09/2008 - 07/2008)
9. Guertin, Marie-Claude: 2 articles (03/2008 - 02/2003)
10. Reeves, François: 2 articles (03/2008 - 02/2003)

Related Diseases

1. Atherosclerosis
2. Inflammation
03/01/2013 - "Succinobucol-eluting stents increase neointimal thickening and peri-strut inflammation in a porcine coronary model."
02/01/2006 - "Two trials test the antioxidant/anti-inflammatory hypothesis with AGI-1067; CART-2 assesses its value for the reduction of both atherosclerosis progression and post-PCI restenosis, and Aggressive Reduction of Inflammation Stops Events (ARISE), which is evaluating its effects on hard cardiovascular outcomes."
12/01/2003 - "Two important trials that test the antioxidant/antiinflammatory hypothesis are ongoing with AGI-1067: the Canadian Atherosclerosis and Restenosis Trial 2, which assesses its value for the reduction of both atherosclerosis progression and post-percutaneous coronary interventions restenosis, and the Aggressive Reduction of Inflammation Stops Events (ARISE) trial which is evaluating its effects on cardiovascular events."
02/06/2003 - "Considering that oxidative stress and inflammation may persist for a prolonged period after stenting, treatment with AGI-1067 for the entire period of risk after PCI (instead of only 4 weeks in CART-1) may result in enhanced protection against luminal renarrowing in the ongoing multicenter CART-2 trial. "
01/01/2002 - "Considering that oxidative stress and inflammation may persist for a prolonged period after stent placement, treatment with AGI-1067 for the entire period of risk after percutaneous coronary intervention (PCI) [instead of only 4 weeks in CART-1] may result in enhanced protection against luminal renarrowing. "
3. Coronary Artery Disease (Coronary Atherosclerosis)
4. Huntington Disease (Huntington's Disease)
5. Acute Coronary Syndrome

Related Drugs and Biologics

1. Probucol (Lorelco)
2. Phenobarbital (Luminal)
3. Succinate Dehydrogenase (Fumarate Reductase)
4. 3-nitropropionic acid
5. glucuronyl glucosamine glycan sulfate (Vessel)
6. succinobucol (AGI 1067)
7. Quercetin
8. Adiponectin
9. PPAR gamma
10. Interferon-beta

Related Therapies and Procedures

1. Stents
2. Balloon Angioplasty